GlassScriptPhysician profile
Jorge M Kourie
NPI 1659585552
$39,076.93
in general payments reported to CMS, 2019-2025
37 companies · $8,347 in 2025
The $8,347 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,638 · 2020: $587 · 2021: $800 · 2022: $2,500 · 2023: $1,090 · 2024: $21K · 2025: $8,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $4,027 · Travel and Lodging: $295 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,055.00 |
| Food and Beverage | $4,026.68 |
| Travel and Lodging | $295.03 |
| Education | $174.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19,360.87 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,755.48 | 2023-2025 | Jardiance |
| Gilead Sciences, INC. | $4,029.48 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $2,042.30 | 2020-2025 | Envarsus |
| Otsuka America Pharmaceutical, INC. | $1,112.05 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $500.45 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $465.07 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $430.53 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $425.03 | 2020-2025 | Tavneos, Aranesp, Parsabiv |
| Calliditas Therapeutics US INC. | $423.26 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $237.64 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $204.30 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $203.18 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $195.15 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $187.14 | 2024-2025 | Prevymis |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $168.57 | 2019 | |
| Xeris Pharmaceuticals, INC. | $143.28 | 2022-2025 | Keveyis |
| Travere Therapeutics, INC. | $142.87 | 2019-2025 | Filspari |
| Akebia Therapeutics INC | $127.38 | 2019-2024 | Vafseo, Auryxia |
| Alnylam Pharmaceuticals INC. | $122.72 | 2020-2021 | |
| Glaxosmithkline, LLC. | $99.85 | 2020-2024 | Benlysta, Jesduvroq |
| American Regent | $80.13 | 2023 | Injectafer |
| Fresenius USA Marketing, INC. | $79.98 | 2019-2024 | Velphoro |
| Ardelyx, INC. | $72.86 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $70.67 | 2022-2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $59.54 | 2019-2025 | Ultomiris |
| Cycle Pharmaceuticals INC | $48.69 | 2024-2025 | Ormalvi, Tiopronin |
| Octapharma USA, INC. | $46.01 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $44.45 | 2021-2022 | |
| Davol INC. | $42.84 | 2024 | Arista Ah Flexitip |
| Kyowa Kirin, INC. | $33.21 | 2023-2025 | Crysvita |
| Nuwellis, INC. | $27.87 | 2022 | |
| Chiesi USA, INC. | $24.68 | 2025 | Elfabrio |
| Renalytix Ai, INC. | $22.74 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Horizon Therapeutics Plc | $16.26 | 2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $16.15 | 2020 | |
| Novo Nordisk INC | $14.25 | 2023 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Kourie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.